The Global Shoulder Arthroplasty Market is expected to reach $ 1,866.3 million by 2023

Posted On December 28, 2017 By OrthoSpineNews In Recon, Top Stories /

NEW YORK, Dec. 28, 2017 /PRNewswire/ — The Global Shoulder Arthroplasty Market was valued at $ 1,090.0 million in 2016, and is expected to reach $ 1,866.3 million by 2023, registering a CAGR of 8.1% during the forecast period. The growth of the global shoulder arthroplasty market is driven due to factors such as increasing incidences of arthritis-associated disorders such as osteoarthritis and rheumatoid arthritis, and growing geriatric population. Also, significant adoption of reverse shoulder arthroplasty by surgeons and growing sports-related injuries have further contributed to the growth of the market. Nevertheless, postoperative complications associated with shoulder arthroplasties and the cost associated with the shoulder arthroplasty devices is the factors that would limit the growth of the market.

Read the full report: https://www.reportlinker.com/p05258049

The shoulder arthroplasty market is segmented based on procedures, devices, indications, end users, and regions. Based on procedures, the market is segmented into partial shoulder arthroplasty, total shoulder arthroplasty, and revision shoulder arthroplasty. Based on devices, the market is segmented into shoulder arthroplasty resurfacing implants, shoulder arthroplasty trauma devices, and shoulder arthroplasty platform systems. Based on indications, the market is segmented into arthritis, fracture/dislocation, rotator cuff tear arthropathy, Hill Sachs defect, and others. Based on end users, the market is segmented into hospitals & clinics and outpatient surgical centers. Based on geography, the market is segmented into North America, Europe, Asia-Pacific, and LAMEA.

The market research report covers the analysis of key stake holders of the leading market participants are Integra LifeSciences Corporation, DJO Global, Zimmer Biomet, Wright Medical Group, Inc. /Tornier Inc., Johnson & Johnson (DePuy Synthes), Smith and Nephew Plc, Arthrex, Inc., Conmed Corporation, Evolutis, and Exactech, Inc.

Read the full report: https://www.reportlinker.com/p05258049

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need – instantly, in one place.

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

Related Links
http://www.reportlinker.com

Global Artificial Joints Market 2017-2021: Driven by Increasing Demand for MI Surgeries – Research and Markets

Posted On December 27, 2017 By OrthoSpineNews In Recon /

December 27, 2017

DUBLIN–(BUSINESS WIRE)–The “Global Artificial Joints Market 2017-2021” report has been added to Research and Markets’offering.

The global artificial joints market is expected to grow at a CAGR of 5.53% during the period 2017-2021.

The report, Global Artificial Joints Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

One trend in the market is increasing demand for MI surgeries. The demand for MI surgeries has been increasing across the world. MI surgeries reduce physical trauma and the risk of infections. This enables patients to recover faster. MI surgeries involve short hospital stay, improve comfort, and enable the early return to work.

According to the report, one driver in the market is increasing incidence of age-related musculoskeletal disorders. Musculoskeletal disorders have been the most common disorder that affects the aging population. The most frequent musculoskeletal disorders among the aging population have been osteoporosis, osteoarthritis, fractures, and infections. With aging, musculoskeletal tissues become fragile, loose cartilage resilience, have reduced ligament elasticity, and loose of muscular strength, which reduce the ability of tissues to perform normal functions.

Key vendors

DePuy Synthes
Smith & Nephew
Stryker
Zimmer Biomet

Other prominent vendors

Arthrex
Acumed
Aesculap Implant Systems
AK Medical
BioPro
DJO Surgical
Extremity Medical
Others

Key Topics Covered:

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03: Research Methodology

Part 04: Introduction

Part 05: Market Landscape

Part 06: Segmentation By Application

Part 07: Segmentation By Product Type

Part 08: Segmentation By End-User

Part 09: Segmentation By Geography

Part 10: Decision Framework

Part 11: Drivers And Challenges

Part 12: Market Trends

Part 13: Vendor Landscape

Part 14: Vendor Analysis

For more information about this report visit https://www.researchandmarkets.com/research/qjthg7/global_artificial

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Orthopedic Devices

Fuse Medical, Inc. Signs Definitive Purchase Agreement to Acquire CPM Medical Consultants, LLC

Posted On December 21, 2017 By OrthoSpineNews In Biologics, Extremities, Recon, Spine /

December 19, 2017

RICHARDSON, Texas–(BUSINESS WIRE)–Fuse Medical, Inc., (OTC: FZMD), (“Fuse” or the “Company”), announced today that it signed a definitive purchase agreement to acquire CPM Medical Consultants, LLC (“CPM”), a privately-owned nationwide distributor of medical device implants and biologics.

CPM is a stocking distributor with an extensive portfolio of orthopedic implants for total joint reconstruction, sports medicine, internal and external fixation products for extremities, and full spinal implants and instrumentation. CPM also offers an extensive assortment of biologics, which include human allograft with cell based products, regenerative tissue, and amniotic fluids to augment all types of surgical procedures.

Fuse expects the transaction to be accretive to 2018, and it anticipates the 2018 consolidated company revenues generated from its product sales and distribution to be at approximately $35 million. The transaction is subject to customary conditions of closing, which is expected to occur by December 31, 2017. Following the transaction, CPM will be a wholly-owned subsidiary of Fuse.

Management Commentary on Acquisition

Christopher C. Reeg, Chief Executive Officer of Fuse, said, “We are thrilled to have the CPM family join the Fuse team, and look forward to welcoming new business associates to Fuse. We are confident that the consolidated Fuse and CPM organizations will provide the necessary platform to achieve our numerous growth and expansion goals.”

“The acquisition of CPM is an ideal complement to our strategic objectives as it brings an experienced and proven distribution organization consisting of direct sales employees, independent sales agents, and sub-distributors who are focused in specific surgical areas. In developing our strategies in this market sector, we believe this new sales channel will provide us with an opportune pipeline for the expansion of national distribution and the launch of new product offerings, both internally developed and acquired,” added Mr. Reeg.

Mark W. Brooks, CPM Founder and Owner, stated, “We are excited with the expected benefits both organizations will gain from this transaction. CPM brings the ideal combination of broad product assortment, sales and distribution, and employee talents in a strategic market sector with outstanding growth potential. We expect our extensive product portfolio to strengthen and complement Fuse.”

“The prospect of combining the collective Fuse and CPM product portfolios is synergistic to both organizations,” commented Mr. Brooks.

About Fuse Medical, Inc.

Fuse provides a broad portfolio of orthopedic implants including internal and external fixation products; upper and lower extremity plating; total joint reconstruction; soft tissue fixation and augmentation for sports medicine procedures; full spinal implants for trauma, degenerative disc disease, and deformity indications; human allografts, substitute bone materials, and tendons; and regenerative tissues and fluids to augment orthopedic surgeries and wound care. For more information about Fuse, please visit: www.fusemedical.com.

Forward-Looking Statements

Certain statements in this press release, including those related to an anticipated purchase of all of the outstanding membership units and plans for the consolidated company, constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based only on information available to the Company as of the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the Securities and Exchange Commission; the failure of the Company to close the transaction; and integration issues with the consolidated company. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events, or otherwise, except as required by law.

Contacts

Fuse Medical, Inc.
Devon Peddie, 469-862-3030
Investor Relations Analyst
Facsimile 469-862-3035
info@Fusemedical.com

Zimmer Biomet Announces Appointment of Bryan C. Hanson as President and Chief Executive Officer

Posted On December 19, 2017 By OrthoSpineNews In Recon, Top Stories /

WARSAW, Ind., Dec. 19, 2017 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that Bryan C. Hanson has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective today. Daniel P. Florin, who has served as Interim CEO since July 11, 2017, will continue in his role as Senior Vice President and Chief Financial Officer.

Larry C. Glasscock, Chairman of the Zimmer Biomet Board of Directors, stated, “On behalf of the Board, I am thrilled to welcome Bryan to the Zimmer Biomet team. The Board of Directors, with the assistance of a leading executive search firm, carefully identified, evaluated and interviewed a number of highly-qualified candidates and concluded that Bryan is the best fit to lead the Company. Bryan is a proven executive with a track record of successfully leading, growing and transforming global medical device businesses to achieve higher levels of innovation, commercial success and profitability. This leadership announcement comes at an important time in Zimmer Biomet’s history, and we look forward to working closely with Bryan to further leverage our leading portfolio of technologies, solutions and personalized services to enhance stockholder value.”

Mr. Hanson joins Zimmer Biomet with more than 20 years of experience in the medical device industry. Most recently, he served as a member of Medtronic’s Executive Committee and as the Executive Vice President and President of Medtronic’s Minimally Invasive Therapies Group, where he oversaw and provided strategic direction to this approximately $9 billion business. Prior to Medtronic, Mr. Hanson served in a number of executive roles of increasing responsibility. In 2013, he was named Group President of Covidien’s Medical Devices business. In 2011, as Surgical Solutions Group President, Mr. Hanson transformed two of Covidien’s largest divisions—Energy-based Devices and Surgical Devices—into one global business unit. Mr. Hanson also serves on the board of AmeriCares, an emergency response and global health organization committed to saving lives and building healthier futures for people in crisis.

Mr. Hanson stated, “I am honored and excited to join the talented team at Zimmer Biomet. I have long admired Zimmer Biomet, including its strong brand, commercial excellence and market-leading salesforce, healthy portfolio of marquee products and strong innovation pipeline. I share the Company’s purpose of improving the quality of life for patients and I look forward to deeply familiarizing myself with Zimmer Biomet’s global operations to ensure we have the right foundation in place to support our customers and the patients they serve around the world, while driving sustained shareholder value.”

Mr. Florin commented, “It has been a privilege to lead the Zimmer Biomet organization as Interim CEO. I join the rest of the management team in welcoming Bryan, and I am confident the Company will thrive under his leadership.”

Mr. Glasscock added, “On behalf of everyone at Zimmer Biomet, I want to thank Dan for serving as the Company’s Interim CEO for the past five months. We are grateful that Dan assumed this role at such an important time, and we look forward to continuing to benefit from his expertise through his ongoing service as CFO.”

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com, or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this release.

ZBH-Corp

SOURCE Zimmer Biomet Holdings, Inc.

Willamette Surgery Center First in Oregon to Receive Advanced Certification for Total Hip and Total Knee Replacement

Posted On December 14, 2017 By OrthoSpineNews In Recon, Top Stories /

SALEM, Ore., Dec. 12, 2017 /PRNewswire/ — Willamette Surgery Center, in partnership with Hope Orthopedics of Oregon, is the first facility in Oregon to receive advanced certification for outpatient total hip and total knee replacement. Advanced Certification for Total Hip and Total Knee Replacement from The Joint Commission focuses on all aspects of outpatient hip and knee replacement, from pre-operative consultation to rehab and follow up visits. This achievement goes above and beyond the Joint Commission Accreditation, which Willamette Surgery Center has achieved and maintained since opening in 1999.

The surgeons of Hope Orthopedics have performed 375 joint replacements at Willamette Surgery Center since the start of the program in 2014.

When asked about the success of the partnership program of Willamette Surgery Center and Hope Orthopedics, Dr. John Coen, Hope Orthopedics surgeon and head of the outpatient total joint replacement program says, “It is great to see validation of something the surgeons at Hope Orthopedics already knew – Willamette Surgery Center does a fantastic job caring for our patients. It is a pleasure for Hope Orthopedics to bring outpatient joint replacement to the people of the Willamette Valley, and Willamette Surgery Center does it right.”

Willamette Surgery Center underwent a rigorous onsite review to qualify for advanced certification. Joint Commission experts evaluated compliance with advanced care standards and total hip and total knee replacement requirements, including orthopedic consultation, and pre-operative, intraoperative and post-surgical follow-up care.

Advanced Certification assures the public that standardized processes are in place to reduce the risk of error and improve the delivery of safe patient care.

About Willamette Surgery Center and Hope Orthopedics: Willamette Surgery Center and Hope Orthopedics are based in Salem, Oregon. Their partnership to bring outpatient total joint replacement to the area began in 2014. You can see more in this video about the outpatient joint replacement process at Hope Orthopedics and WSC.

Founded in 1951, The Joint Commission seeks to improve health care for the public by evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value. An independent, nonprofit organization, The Joint Commission is the nation’s oldest and largest standards-setting and accrediting body in health care. Learn more about The Joint Commission at www.jointcommission.org.

SOURCE Willamette Surgery Center

AAOS approves diagnostic and treatment criteria for osteoarthritis of the hip

Posted On December 13, 2017 By OrthoSpineNews In Recon, Top Stories /

ROSEMONT, Ill., Dec. 12, 2017 /PRNewswire-USNewswire/ — The American Academy of Orthopaedic Surgeons (AAOS) Board of Directors approved new Appropriate Use Criteria (AUC) for Management of Osteoarthritis of the Hip.

The AAOS AUCs provide clinicians with algorithms on how to optimally treat an orthopaedic injury or condition, including hypothetical scenarios and possible treatments, ranked for appropriateness based on the latest research and clinical expertise and experience.

The new AUC supports the Clinical Practice Guideline, “Management of Osteoarthritis of the Hip” that strongly recommends:

The use of pre-surgical treatments to ease pain and improve mobility, including corticosteroid injections, physical therapy and non-narcotic medication (specifically acetaminophen, non-steroidal anti-inflammatory drugs or tramadol) for pain.
Both anterior and posterior approaches for total hip replacement (THR) surgery.

In addition, the new criteria highlight when “hip replacement may be appropriate even when patients have modifiable risk factors, such as obesity, mental health disorders, smoking and diabetes,” said Robert H. Quinn, MD, AAOS AUC section leader on the Committee on Evidence-Based Quality and Value.

For example, “some patients, who have worked closely with their medical team to best mitigate these risk factors, might be considered on an individual basis” for surgery, said Dr. Quinn. “In these instances, the doctor and patient must weigh the benefits and risks of surgery. At the end of the day it’s one surgeon and one patient, and hopefully both are considering the optimal treatment, based on the patient’s particular condition and diagnosis.”

The AUC and CPG, “Management of Osteoarthritis of the Hip,” are available through the AAOS OrthoGuidelines website and mobile app.

More Information about the AAOS
With more than 38,000 members, the American Academy of Orthopaedic Surgeons is the world’s largest medical association of musculoskeletal specialists. The AAOS provides educational programs for orthopaedic surgeons and allied health professionals, champions and advances the highest quality musculoskeletal care for patients, and is the authoritative source of information on bone and joint conditions, treatments and related issues.

Visit AAOS, at:
Newsroom.aaos.org for bone and joint health news, stats, facts, images and interview requests.
Orthoinfo.org for patient information on hundreds of orthopaedic diseases and conditions. ANationinMotion.org for inspirational patient stories, and orthopaedic surgeon tips on maintaining bone and joint health, avoiding injuries, treating musculoskeletal conditions and navigating recovery.
Facebook.org/AAOS1
Twitter.com/AAOS1
Instagram.com/AAOS_1

SOURCE American Academy of Orthopaedic Surgeons

THINK Surgical, Inc. Receives CE Mark Approval for the TSolution One® Surgical System for Total Knee Arthroplasty

Posted On December 13, 2017 By OrthoSpineNews In Recon, Regulatory, Robotics /

FREMONT, Calif., Dec. 11, 2017 /PRNewswire/ — THINK Surgical Inc., a global medical device manufacturer of the only active robotic surgical system for orthopaedic surgery, announces that it has received CE Mark approval for the TSolution One® Surgical System, bringing active robotic precision to Total Knee Arthroplasty (TKA).

The TSolution One Surgical System first entered the European market in 2015 when it received CE Mark approval for Total Hip Arthroplasty (THA). Currently, the system has 510(k) clearance for THA in the United States and four centers are enrolling patients for an IDE clinical study for TKA. Earlier in the year, the TSolution One Surgical System received Korean-FDA clearance for both THA and TKA. It also received approval for sale in Israel by the Ministry of Health for THA.

“We are pleased to offer one of the most advanced technologies in Total Knee Replacement through the TSolution One Surgical System to the European market and other countries that rely on the CE Mark,” said John Hahn, CEO of THINK Surgical, Inc. “Obtaining the CE Mark represents a key milestone towards continuing the global commercialization of our differentiated robotic technology and our commitment to improving patients’ lives and partnering with surgeons to transform orthopedic surgery.”

TSolution One is a robotic system that enables surgeons to create the patient’s personalized pre-surgical joint replacement plan, using CT-based 3D planning and the system’s open implant library to achieve an optimized surgical plan. During surgery, the robot precisely executes the patient’s individual surgical plan by removing diseased bone and preparing the bone cavity and joint surface with sub-millimeter dimensional accuracy.¹THINK’s active robotic technology has been shown to improve joint replacement implant fit and alignment as compared to conventional joint replacement surgery.² Accurate implant fit and alignment may be responsible for reduced postoperative pain, complications, and improved patient function.^3,4

¹Paul HA, Bargar WL, Mittlestadt B, Musits B, Taylor RH, Kazanzides P, et al. Development of a Surgical Robot for Cementless Total Hip Arthroplasty. Clin Orthop Relat Res 1992;285:57–66

²Netravali, Nathan et al., “A Perspective on Robotic Assistance for Knee Arthroplasty” Advances in Orthopedics (2013): DOI http://dx.doi.org/10.1155/2013/970703

³P. F. Choong, M. M. Dowsey, and J. D. Stoney, “Does accurate anatomical alignment result in better function and quality of life? Comparing conventional and computer-assisted total knee arthroplasty,” Journal of Arthroplasty, vol. 24, no. 4, pp. 560–569, 2009.

⁴Barrack RL. Dislocation after total hip arthroplasty: Implant design and orientation. J Am Acad Orthop Surg. 2003;11(2):89-99.

About THINK Surgical, Inc.
THINK Surgical, Inc. is committed to the future of orthopaedic surgery and to improving patient care through the development of leading-edge precision technology. THINK Surgical develops, manufactures, and markets the only active robotic surgical system for orthopaedic surgery.

For more information, visit www.THINKSurgical.com.
TSolution One® is a registered trademark of THINK Surgical, Inc.

Contact: Nancy Heinzer
510-249-2318
info@thinksurgical.com

Related Links
THINK Surgical website

SOURCE THINK Surgical, Inc.

Next-Generation High-Definition Visualization System for Minimally Invasive Surgery Introduced by DePuy Synthes

Posted On December 6, 2017 By OrthoSpineNews In Recon, Spine, Top Stories /

LAS VEGAS, Dec. 6, 2017 /PRNewswire/ — Today, the PUREVUE™ Visualization System was unveiled at the Orthopaedic Summit 2017: Evolving Techniques. This new offering from DePuy Synthes*, part of the Johnson & Johnson Medical Devices Companies**, is a state-of-the-art imaging platform for minimally invasive endoscopic surgery.

Approximately 18.6 million endoscopic procedures are performed each year in the United States.¹ In these procedures, case efficiency and patient outcomes are often linked to how well the surgeon can see the targeted anatomy.

The PUREVUE Visualization System combines a light source, image processer and local image management for a reduced operating room (OR) footprint, and includes intuitive touch-screen navigation and customizable settings for many minimally invasive surgery (MIS) applications. The autoclavable camera head features a proprietary sensor designed for endoscopy, that delivers native HD image acquisition for a clear view throughout the procedure that is further enhanced by multiple monitor options, including ultra-high-definition 4K. The forward-compatible system is also augmented by a wide range of visualization accessories.

“With Americans living longer and seeking shorter recovery times, the call for minimally invasive procedures is accelerating,” said Stephanie Chamberlain, Vice President and Global Platform Leader, DePuy Synthes Mitek Sports Medicine. “We are committed to bringing forward innovation that responds to evolving patient needs and the PUREVUE Visualization System is an example of how our advanced technologies enable high quality patient care.”

The PUREVUE Visualization System also completes the company’s capital equipment offering in arthroscopy, a type of endoscopic surgery focused on joint anatomy, which includes the VAPR VUE™ Radiofrequency System and the FMS VUE™ Fluid Management and Tissue Debridement System. Together, these solutions bolster Mitek Sport Medicine’s portfolio of implants and instrumentation used for a wide spectrum of arthroscopic soft tissue procedures.

About DePuy Synthes
DePuy Synthes, part of the Johnson & Johnson Medical Devices Companies, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

¹ Perry, Anne F., et al. “Burden of Gastrointestinal Disease in the United States: 2012 Update” Gastroenterology. 2012 November; 143(5): 1179–1187.e3. doi:10.1053/j.gastro.2012.08.002 Update.

*DePuy Synthes represents the products and services of DePuy Synthes, Inc. and its affiliates.
**The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson’s Medical Devices segment.

DSUS/MTK/1117/1100(1)
December 2017

SOURCE DePuy Synthes

Amplitude Surgical: Commercial Launch of the ACLip®, an Innovation in (ACL) Reconstruction Knee Surgery

Posted On December 5, 2017 By OrthoSpineNews In Recon /

December 04, 2017

VALENCE, France–(BUSINESS WIRE)–Regulatory News:

Amplitude Surgical (ISIN: FR0012789667, Ticker: AMPLI, PEA-PME eligible) (Paris:AMPLI), a leading French player on the global surgical technology market for lower-limb orthopedics, announces the commercial launch of the AClip®, its innovation in anterior cruciate ligament (ACL) reconstruction knee surgery.

Olivier Jallabert, Chairman and CEO of Amplitude Surgical, says: “Following its hip and knee joint prosthetics and its foot surgery implants, Amplitude Surgical’s offering is being expanded to sports surgery. Repairing the anterior cruciate ligament is one of the most frequent knee pathologies, with almost 250,000 operations performed each year in Europe. The AClip® is a highly differentiating innovation resulting from our R&D activity, after over 6 years of development and a number of patents. Like Novastep, and in synergy with our innovative offering for lower limbs, the AClip® should provide a significant contribution to the Group’s future growth.”

Following the successful implantation of more than 850 AClip® implantsin surgical assessment center, Amplitude Surgical can now begin the widespread distribution of this ACL repair device. This innovation is unique to the market, and will be presented at the annual congress of the Société Francophone d’Arthroscopie (Francophone Arthroscopy Society) in Marseille.

The Aclip implant for anterior cruciate ligament repair provides surgeons with an unique, simple, and reproduceable repair device. The insertion of the AClip® is achieved under arthroscopic surgery, typically as an outpatient procedure. The rigidity of this fixation boosts the integration of the implant and could accelerate the patient’s rehabilitation and return to activity. Since the ACLip® received CE marking in Europe, the registration process has been ongoing in the United States and the registration application is due to be filed with the FDA shortly.

The implant is characterized by a two-part fixation system (cage & endobutton), which is extremely resistant to traction and has a unique set of instruments featuring a dual-level reamer. This allows for two bone tunnels of different diameters to be drilled at the same time.

About Amplitude Surgical
Founded in 1997 in Valence, France, Amplitude Surgical is a leading French player on the global surgical technology market for lower-limb orthopedics. Amplitude Surgical develops and markets high-end products for orthopedic surgery covering the main disorders affecting the hip, knee and extremities, and notably foot and ankle surgery. Amplitude Surgical develops, in close collaboration with surgeons, numerous high value-added innovations in order to best meet the needs of patients, surgeons and healthcare facilities. A leading player in France, Amplitude Surgical is developing abroad through its subsidiaries and a network of exclusive distributors and agents distributing its products in more than 30 countries. Amplitude Surgical operates on the lower-limb market through the intermediary of its Novastep subsidiaries in France and the United States. At June 30, 2017, Amplitude Surgical had a workforce of nearly 370 employees and recorded sales of over 93 million euros.

Contacts

Amplitude Surgical
Philippe Garcia
CFO
finances@amplitude-surgical.com
+33 (0)4 75 41 87 41
or
NewCap
Investor Relations
Marc Willaume
amplitude@newcap.eu
+33 (0)1 44 71 00 13
or
NewCap
Media Relations
Nicolas Merigeau
amplitude@newcap.eu
+33 (0)1 44 71 94 98

Smith & Nephew’s NAVIO™ Surgical System launches the first robotics-assisted bi-cruciate retaining total knee replacement

Posted On November 13, 2017 By OrthoSpineNews In Recon, Robotics, Top Stories /

13 November 2017

Smith & Nephew (NYSE:SNN; LSE:SN), the global medical technology business, today announces completion of the world’s first robotics-assisted bi-cruciate retaining total knee replacement procedures.

The NAVIO robotics-assisted surgical system aids in implanting the JOURNEY™ II XR (bi-cruciate retaining total knee system) which is one of the only total knee designs allowing retention of the ACL, and is designed to improve patient satisfaction. ¹

With this launch, NAVIO now offers both partial and total knee options that include the first and only robotics-assisted bi-cruciate retaining knee procedure, commercially available today.

Drs. Vivek Neginhal (WV), David Rovinsky(HI), and David Fabi (CA) recently performed the first cases. “I believe that the NAVIO is able to provide critical elements of success for the JOURNEY II XR, such as accuracy of tibia component placement and a streamlined surgical technique.” Dr. Neginhal further commented: “I was amazed at how fluid the knee motion was on the first postop day. My patients have expressed great satisfaction so far. I believe that NAVIO’s accuracy and flexibility of use combined with JOURNEY II XR’s retention of the patient’s cruciate ligaments and physiological design will truly increase patients’ function and satisfaction.”

The NAVIO is a next generation handheld robotics platform designed to aid surgeons with implant alignment, ligament balancing and bone preparation – key factors that can drive implant survivorship.^2,3 The small footprint of NAVIO allows for set up and portability. Furthermore, the NAVIO robotics-assisted system does not require a preoperative image, such as a CT scan. This allows patients to receive the benefits of robotics-assistance without the extra steps, costs, and radiation associated with additional preoperative imaging.⁴

“The JOURNEY II XR bi-cruciate retaining knee has the potential to deliver the best possible outcome for the surgeon and patient through the preservation of important anatomical structures such as the ACL. The NAVIO robotics-assisted surgical system enables accurate tibial implant placement to deliver a more reproducible surgical technique. We are proud to be the only company to offer the unique combination of NAVIO robotics-assistance and the JOURNEY II XR Knee System,” said Mike Donoghue, Senior Vice President of Global Marketing, Orthopaedics at Smith & Nephew.

References

Moro-Oka, Taka-Aki, Marc Muenchinger, Jean Pierre Canciani, and Scott A. Banks.“Comparing in Vivo
Kinematics of Anterior Cruciate-retaining and Posterior Cruciate-retaining Total Knee Arthroplasty.” Knee
Surgery, Sports Traumatology, Arthroscopy 15.1 (200&): 93:99. Web.
Sharkey, P., et al. “Why Are Total Knee Arthroplasties Failing Today?” Clinical Orthopaedics and Related Research. 2002 Nov;404:7-13.
Siddique, N., Ahmad, Z. “Revision of Unicondylar to Total Knee Arthroplasty: A Systematic Review” The Open Orthopaedics Journal 2012;6; (Suppl 2: M2) 268-275
Sg2 Healthcare Intelligence. Technology Guide: Orthopedic Surgical Robotics. 2014.25. Readmissions Reduction Program (HRRP). CMS.gov. Page last Modified: 04/18/2016 5:08 PM.

Enquiries

Media
Charles Reynolds	+44 (0) 1923 477314
Smith & Nephew

Dave Snyder	+1 (978) 749-1440
Smith & Nephew

Simon Conway / Debbie Scott	+44 (0) 20 3727 1000
FTI Consulting

Investors
Ingeborg Øie	+44 (0) 20 7960 2285
Smith & Nephew

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people’s lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were almost $4.7 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).

For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.

^{Forward-looking Statements}

^{This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as “aim”, “plan”, “intend”, “anticipate”, “well-placed”, “believe”, “estimate”, “expect”, “target”, “consider” and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew’s most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew’s expectations.}

^{◊ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.}